SAB Biotherapeutics, Inc. SABS
3.12 USD +0.01 (+0.32%)
Nov 12, 2026, 1:31 PM EST
3.01 Day range 3.22
2.44 52-week range 5.15
- YTD
- -16.58%
- 1 year
- -8.50%
SABS revenue history
Revenue is income from the company’s ordinary business activities.
0 USD
FY 2025 · Period ended
Coverage: complete. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Scroll the table to see all values →
| Fiscal period | Period end | Revenue | YoY change | YoY % |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | 0 | -1,322,410 | -100.00% |
| FY 2024 | 2024-12-31 | 1,322,410 | -916,581 | -40.94% |
| FY 2023 | 2023-12-31 | 2,238,991 | -21,665,190 | -90.63% |
| FY 2022 | 2022-12-31 | 23,904,181 | -36,971,897 | -60.73% |
| FY 2021 | 2021-12-31 | 60,876,078 | 5,638,319 | 10.21% |
| FY 2020 | 2020-12-31 | 55,237,759 | 51,795,952 | 1504.91% |
| FY 2019 | 2019-12-31 | 3,441,807 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2026-11-09T07:00:38.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.